Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Protein Implicated in Aberrant B-cell Survival in Transplant Disease

By BiotechDaily International staff writers
Posted on 27 Aug 2012
Ex vivo study finds that B-cells from patients with chronic graft vs. host disease (cGVHD) are in a heightened metabolic state and are resistant to apoptosis compared to patients without cGVHD, and leads to identification of a key candidate target for development of more effective drug therapies.

The research team, primarily from University of North Carolina’s Lineberger Comprehensive Cancer Center (UNC Lineberger; Chapel Hill, NC, USA), performed ex vivo analyses of peripheral B cells from 51 patients who either had or did not have active cGVHD and were greater than one year from the time of allogeneic hematopoietic stem cell (HSCT) transplantation. In addition to the finding of the aberrantly sustained activation of the B-cells from patients with cGVHD, an investigation into the mechanisms involved in this process led to the implication of a mechanistic link between this abnormal B-cell survival and the TNF family member signaling protein called BAFF, thus identifying BAFF as having an important role in the pathogenesis of cGVHD.

For patients who received bone marrow or stem cells, it is estimated that 40%-70% may experience chronic GVHD.

“Steroids are currently our only standard treatment for chronic GVHD and they are often not effective,” noted senior author Stefanie Sarantopoulos, MD, PhD, assistant professor in the division of hematology/oncology and the departments of microbiology and immunology at the UNC School of Medicine. This study offers BAFF and the BAFF-mediated signaling pathways that contribute to this “revved up” B-cell activity as potentially suitable sources of novel therapeutic targets for chronic GVHD patients.

The study was published August 15, 2012, in the journal Blood.

Related Links:

University of North Carolina’s Lineberger Comprehensive Cancer Center




Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.